{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:55:09Z","timestamp":1792234509350,"version":"4.4.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,14]]},"DOI":"10.1093\/eurheartj\/eht187","type":"journal-article","created":{"date-parts":[[2013,5,27]],"date-time":"2013-05-27T20:09:13Z","timestamp":1369685353000},"page":"2453-2463","source":"Crossref","is-referenced-by-count":569,"title":["Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial"],"prefix":"10.1093","volume":"34","author":[{"given":"Bertram","family":"Pitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Kober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Gheorghiade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Nowack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,5,27]]},"reference":[{"key":"key\n\t\t\t\t20170626083020_EHT187C1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626083020_EHT187C2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626083020_EHT187C3","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626083020_EHT187C4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","article-title":"2009 Focused update incorporated into the ACC\/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"53","author":"Hunt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626083020_EHT187C5","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"Abstract Supplement","key":"key\n\t\t\t\t20170626083020_EHT187C6","first-page":"772","article-title":"Cardiorenal protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical model of hypertension and diastolic heart failure","volume":"33","author":"Delbeck","year":"2012","journal-title":"Eur Heart J"},{"issue":"Abstract Supplement","key":"key\n\t\t\t\t20170626083020_EHT187C7","first-page":"978","article-title":"Improved survival and nephroprotection in hypertensive rats by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist","volume":"33","author":"Kolkhof","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626083020_EHT187C8","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20170626083020_EHT187C9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626083020_EHT187C10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cardfail.2008.03.003","article-title":"Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much?","volume":"14","author":"Mak","year":"2008","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t20170626083020_EHT187C11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11897-009-0017-5","article-title":"Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?","volume":"6","author":"Pitt","year":"2009","journal-title":"Curr Heart Fail Rep"},{"key":"key\n\t\t\t\t20170626083020_EHT187C12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t20170626083020_EHT187C13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"Abstract Supplement","key":"key\n\t\t\t\t20170626083020_EHT187C14","first-page":"7","article-title":"Pronounced cardiac protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical rat model of heart failure","volume":"33","author":"Albrecht-K\u00fcpper","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626083020_EHT187C15","first-page":"A10732","article-title":"BAY 94-8862 exerts a potent natriuretic effect in healthy male subjects pre-treated with fludrocortisone: findings from a proof-of-concept study","volume":"126","author":"Lentini","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626083020_EHT187C16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/eurjhf\/hfq049","article-title":"Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)","volume":"12","author":"Zannad","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20170626083020_EHT187C17","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/34\/31\/2453\/17896659\/eht187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T22:38:19Z","timestamp":1503441499000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/eht187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,27]]},"references-count":17,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2013,5,27]]},"published-print":{"date-parts":[[2013,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/eht187","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718013671.793497213","asserted-by":"object"}]},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5,27]]}}}